Pharmacy-Driven Diabetes Technology Adoption Will Support A Stronger Long-Term Outlook

Catalysts

About Beta Bionics

Beta Bionics develops automated insulin delivery systems aimed at simplifying diabetes management for people using insulin pumps.

What are the underlying business or industry changes driving this perspective?

• The iLet system is attracting a large share of new users from multiple daily injections and from competing pumps, which broadens the addressable base of pump users and can support sustained net sales growth as more patients transition into the installed base.
• Expanding reimbursement through the pharmacy channel, supported by formulary coverage with major PBMs and increasing health plan adoption, is making access easier and tends to carry higher margin recurring supply revenue that can support gross margin and earnings.
• The Mint patch pump, with its 2 piece design, over the air firmware updates and alignment with the existing algorithm, targets patients who prefer a patch format and could open an additional pump segment that supports future revenue and scale driven gross margin gains once commercialized.
• Development of the bihormonal system and associated glucagon asset, including completed PK/PD work and planned feasibility studies, positions the company to address more complex diabetes needs, which can support longer term revenue opportunities and higher value per user if these products reach the market.
• Ongoing iLet software and usability updates, such as improved cartridge change workflow and alert management, along with high reported patient retention in the pharmacy base, support user satisfaction and recurring supply revenue, which can help gross margins and operating leverage as the installed base grows.
• A strong cash position of about US$274 million and management’s view that the company is funded for key initiatives and free cash flow generation ahead of some peers, reduces funding risk around the pipeline and commercialization efforts, which can support more stable earnings progression as scale improves.

Assumptions

This narrative explores a more optimistic perspective on Beta Bionics compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming Beta Bionics's revenue will grow by 47.3% annually over the next 3 years.
• The bullish analysts are not forecasting that Beta Bionics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Beta Bionics's profit margin will increase from -87.9% to the average US Medical Equipment industry of 12.9% in 3 years.
• If Beta Bionics's profit margin were to converge on the industry average, you could expect earnings to reach $36.6 million (and earnings per share of $0.79) by about February 2029, up from $-77.8 million today.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 62.9x on those 2029 earnings, up from -7.7x today. This future PE is greater than the current PE for the US Medical Equipment industry at 31.0x.
• The bullish analysts expect the number of shares outstanding to grow by 1.56% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.67%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Beta Bionics is still investing heavily in growth, with total operating expenses of US$32.2 million in the quarter supported by expanded sales, R&D for Mint and the bihormonal system, and public company costs. If revenue growth moderates while this higher cost base remains, earnings and net margins could stay under pressure for longer than bullish expectations assume, which would weigh on future earnings.
• The Form 483 related to complaint handling and MAUDE reporting, along with the planned re filing of all historical complaints through to the end of Q2 2026, keeps regulatory scrutiny elevated for an extended period. If any findings or perception issues arise from the higher number of published entries, this could affect physician and payer confidence, which would put revenue growth and gross margin expansion at risk.
• The growth story relies on sustained pharmacy channel adoption and high patient retention in a subscription style model. However, stocking swings, uncertainty around how far pharmacy mix can progress for a durable pump, and potential changes in PBM or health plan behavior create long term risk that recurring supply revenue and gross margins do not scale as expected, which would affect both net margins and free cash flow.
• Key pipeline programs such as Mint and the bihormonal system require successful 510(k) or NDA pathways, long clinical timelines, and manufacturing readiness. Any delay, redesign, or regulatory hurdle over the coming years could limit the ability to reach additional patient segments, which would cap long term revenue potential and scale benefits to earnings.
• The business is expanding into underpenetrated pump segments and off label type 2 use in a market that management describes as highly competitive. If larger or new competitors gain share through pricing, features, or broader labels, Beta Bionics could see slower new patient starts or higher churn, which would directly pressure revenue, gross margin, and ultimately earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for Beta Bionics is $40.0, which represents up to two standard deviations above the consensus price target of $29.36. This valuation is based on what can be assumed as the expectations of Beta Bionics's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $40.0, and the most bearish reporting a price target of just $17.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $283.3 million, earnings will come to $36.6 million, and it would be trading on a PE ratio of 62.9x, assuming you use a discount rate of 7.7%.
  
• Given the current share price of $13.7, the analyst price target of $40.0 is 65.8% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.